Compare Recursion Pharmaceuticals Inc (RXRX) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs WD 40 Company — how do they compare? Recursion Pharmaceuticals Inc trades at $3.98 (market cap $2.31B), while WD 40 Company trades at $203.44 (market cap $2.71B). The key difference: WD 40 Company is the larger of the two by market cap, and WD 40 Company pays a 2.02% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and WD 40 Company for 22 Days on average.
| RXRX | WDFC | |
|---|---|---|
Market Cap | $2.31B | $2.71B |
Volume | 40,478,768 | 99,290 |
Sector | Health | Basic Materials |
52-Week High | $6.79 | $264.91 |
52-Week Low | $2.84 | $187.52 |
Typical Hold Time | 22 Days | 22 Days |
Enterprise Value | $1.83B | $2.76B |
Dividend Yield | — | 2.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.27, down 7.78% today, with a bullish technical signal from moving averages but negative profitability. The company reported a net loss of -$644.76M in 2025, with revenue of $74.26M, and has beaten earnings estimates in two of the last three quarters. Recent news highlights strategic AI partnerships and pipeline expansion, though financial performance remains challenged.
The outlook is mixed: analyst consensus is 40% buy, 60% hold, with no sell ratings, indicating cautious optimism for long-term AI-driven growth. Key risks include persistent cash burn, high valuation multiples, and slow revenue growth. Upside depends on successful drug development and partnership milestones, but near-term profitability remains elusive.
WD-40 Company (WDFC) trades at $201.50, down 1.31% on the day, with technical indicators showing a bearish trend. The company maintains strong fundamentals with 55.82% gross margins and 13.22% net income margin, though recent earnings showed mixed results with two beats and one miss. Analyst consensus is mixed with 71% hold ratings despite a $475 price target, while institutional buying activity remains active. Recent news highlights strategic growth initiatives including global expansion and new CFO leadership.
The stock presents a cautious outlook with strong profitability offset by premium valuations (P/E 30.64) and technical weakness. Upside potential exists from the significant analyst price target premium, but risks include margin pressure from input costs and execution challenges in international markets. Current levels near support at $198-200 may offer entry points for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
